Zydus Pharmaceuticals (USA) Inc gets final US FDA approval to market Roflumilast tablets

Summary:

Zydus, being one of the first applicants for Roflumilast Tablets, 500 mcg, is eligible for 180 days of shared generic drug exclusivity, Cadlia Healthcare said in a regulatory filing.

Cadlia Healthcare Ltd on Monday said group firm Zydus Pharmaceuticals (USA) Inc has received final approval from the US health regulator to market its generic version of Roflumilast tablets in the strength of 500 mcg indicated to reduce the risk of chronic obstructive pulmonary disease (COPD) exacerbations.

Zydus, being one of the first applicants for Roflumilast Tablets, 500 mcg, is eligible for 180 days of shared generic drug exclusivity, Cadlia Healthcare said in a regulatory filing.

The US Food and Drug Administration (USFDA) has also given a tentative approval for Roflumilast tablets, 250 mcg 

The US Food and Drug Administration (USFDA) has also given a tentative approval for Roflumilast tablets, 250 mcg, the company added. The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad.

Roflumilast tablets are indicated as a treatment to reduce the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations, it added.

The group now has 327 approvals and has so far filed over 400 abbreviated new drug applications (ANDAs) since the commencement of the filing process in FY 2003-04.

Roflumilast

Roflumilast, sold under the trade name Daxas among others, is a drug that acts as a selective, long-acting inhibitor of the enzyme phosphodiesterase-4.Roflumilast is in a class of medications called phosphodiesterase inhibitors. It works by decreasing swelling in the lungs.

INDICATION. Roflumilast is indicated as a treatment to reduce the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations. This medication is not a bronchodilator, and it is not indicated for the treatment of acute bronchospasm.

 

For more Information: Sign in Websites for Agrochemical & Pharmaceutical Databases:

Website : https://www.chemrobotics.com/ (Agrochemical Databases)

Website : https://chemroboticspharma.com/  (Pharmaceutical Databases)

 

 

Related posts

FRAC 2024 POSTER PUBLISHED: INTRODUCTION OF TAVABOROLE ACTIVE INGREDIENT IN GROUP 54

August 2023 Approval Update: Sage and Biogen’s Zurzuvae™ (Zuranolone) notched FDA approval for the Treatment of Women with Postpartum Depression

March 2023 Approval Update – Pharming’s Leniolisib Gains FDA Approval for Treatment for Activated Phosphoinositide 3-Kinase Delta Syndrome